Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE PRESERVATIVE FREE versus RASUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE PRESERVATIVE FREE versus RASUVO.
METHOTREXATE PRESERVATIVE FREE vs RASUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby inhibiting thymidylate and purine synthesis, leading to impaired DNA synthesis, repair, and cellular replication. It also exhibits immunomodulatory and anti-inflammatory effects through adenosine-mediated pathways.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
Rheumatoid arthritis: 7.5 mg orally once weekly. Psoriasis: 10-25 mg orally once weekly. Neoplastic diseases: IV or IM 30-40 mg/m² once weekly, or oral 2.5-5 mg every 12 hours for 3 doses once weekly. Intrathecal: 12 mg/m² (maximum 15 mg) every 2-7 days.
Subcutaneous injection: 200 mg once weekly.
None Documented
None Documented
Terminal elimination half-life is 3-10 hours for low doses (≤50 mg/m²) and 8-15 hours for high doses (>1 g/m²); prolonged to 24-48 hours in patients with third-space effusions or renal impairment.
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Renal excretion (80-90% as unchanged drug via glomerular filtration and active tubular secretion; enterohepatic recirculation occurs; fecal elimination <10%).
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Category D/X
Category C
Antimetabolite
Antimetabolite